natgillin/translations-raw huggingface dataset:
Effects of nicotinic acid on other medicinal products
Učinki nikotinske kisline na druga zdravila
Effects of other active substances on anagrelide
Učinki drugih zdravilnih učinkovin na anagrelid
Effects of other agents on the pharmacokinetics of brivaracetam
Učinki drugih zdravilnih učinkovin na farmakokinetiko brivaracetama
Effects of other medicinal products on alirocumab
Vpliv drugih zdravil na alirokumab
Effects of other medicinal products on celecoxib
Vplivi drugih zdravil na celekoksib
Effects of other medicinal products on cobimetinib
Učinki drugih zdravil na kobimetinib
Effects of other medicinal products on darifenacin
Delovanje drugih zdravil na darifenacin
Effects of other medicinal products on Deltyba
Učinki drugih zdravil na zdravilo Deltyba
Effects of other medicinal products on dexamethasone
Vpliv drugih zdravil na deksametazon
Effects of other medicinal products on duloxetine
Učinki drugih zdravil na duloksetin Antacidi in antagonisti H2:
Effects of other medicinal products on intravenous sildenafil
Učinki drugih zdravil na intravenski sildenafil
Effects of other medicinal products on Lojuxta and other forms of interaction
Učinki drugih zdravil na zdravilo Lojuxta in druge oblike interakcij
Effects of other medicinal products on mercaptopurine
Učinki drugih zdravil na merkaptopurin
Effects of other medicinal products on nicotinic acid
Učinki drugih zdravil na nikotinsko kislino
Effects of other medicinal products on pharmacokinetics of prucalopride
Učinki drugih zdravil na farmakokinetiko prukaloprida
Effects of other medicinal products on posaconazole
Vplivi drugih zdravil na posakonazol
Effects of other medicinal products on posaconazole:
Učinki drugih zdravil na posakonazol:
Effects of other medicinal products on sildenafil In vitro studies:
Učinki drugih zdravil na sildenafil Raziskave in vitro:
Effects of other medicinal products on the pharmacokinetics of esomeprazole
Učinki drugih zdravil na farmakokinetiko esomeprazola
Effects of other medicinal products on ticagrelor
Učinki drugih zdravil na ticagrelor
Effects of other substances on bexarotene: no formal studies to evaluate interactions with bexarotene have been conducted.
Učinki drugih snovi na beksaroten: Dosedaj ni bilo opravljenih študij za ovrednotenje medsebojnega delovanja beksarotena z drugimi zdravili.
Effects of other substances on dabrafenib
Vpliv drugih snovi na dabrafenib
Effects of P-gp and breast cancer resistance protein (BCRP) inhibitors on afatinib
Učinki zaviralcev P-glikoproteina (P-gp) in proteina odpornosti pri raku dojke (BCRP - breast canacer resistance protein) na afatinib
Effects of prucalopride on pharmacokinetics of other medicinal products
Učinki prukaloprida na farmakokinetiko drugih zdravil
Effects of Rasilez on mortality and cardiovascular morbidity are currently unknown.
Vplivi zdravila Rasilez na umrljivost in kardiovaskularno obolevnost trenutno niso znani.
Effects of repeated administration of fenofibrate on the pharmacokinetics of single or multiple doses of simvastatin have been investigated in two small studies (n=12) followed by a larger one (n= 85) in healthy subjects.
Učinke večkratnega dajanja fenofibrata na farmakokinetiko enojnega ali večkratnih odmerkov simvastatina so preučevali na zdravih osebah v dveh manjših študijah (n=12), ki jima je sledila večja študija (n=85).
Effects of rimonabant on pre- and post-natal development were assessed in the rat at doses up to
Vplive rimonabanta na pre- in postnatalni razvoj so raziskali pri podganah v odmerkih do
Effects of sildenafil on other medicinal products In vitro studies:
Učinki sildenafila na druga zdravila Raziskave in vitro:
Effects of sildenafil on other medicinal products In vitro studies:
Učinki sildenafila na druga zdravila Študije in vitro:
Effects of siltuximab on fertility have not been evaluated in humans.
Pri ljudeh vpliva siltuksimaba na plodnost niso preučevali.
Effects of the disease itself or of its treatment might influence your ability to drive or to use machines.
Vplivi same bolezni ali zdravljenja bolezni lahko vplivajo na vašo sposobnost upravljanja vozil ali uporabe strojev.
Effects of the medicinal product on the immune system of the newborn have not been studied.
Učinki zdravila na imunski sistem novorojenca niso bili preučeni.
Effects of vemurafenib on CYP substrates
Vplivi vemurafeniba na substrate CYP
Effects of vemurafenib on other medicinal products
Vplivi vemurafeniba na druga zdravila
Effects of vortioxetine on the Digit Symbol Substitution Test (DSST), the University of California San Diego Performance-Based Skills Assessment (UPSA) (objective measures) and Perceived Deficits Questionnaire (PDQ) and Cognitive and Physical Functioning Questionnaire CPFQ (subjective measures) scores
Učinki vortioksetina na testu zamenjave številčnih simbolov (DSST – Digit Symbol Substitution Test), testu za ocenjevanje spretnosti, ki temelji na izvedbi Univerze Kalifornija San Diego (UPSA - University of California San Diego Performance-Based Skills Assessment (objektivna merila) in rezultati vprašalnika zaznavanja primanjkljajev (PDQ - Perceived Deficits Questionnaire) ter vprašalnika kognitivnega in telesnega funkcioniranja (CPFQ - Cognitive and Physical Functioning Questionnaire) (subjektivna merila)
Effects on ability to drive and to use machines following treatment by 64Cu-labelled medicinal products is specified in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Vpliv na sposobnost vožnje in upravljanja s stroji po zdravljenju z zdravili, označenimi z bakrom (64Cu), so natančno opisani v povzetku glavnih značilnosti zdravila/navodilu za uporabo določenega zdravila, ki bo radioaktivno označeno.
Effects on ability to drive and to use machines following treatment by Yttrium (90Y)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Vplivi na sposobnost vožnje in upravljanje s stroji po zdravljenju z zdravilom, označenim z itrijem (90Y), bodo natančno opisani v povzetku glavnih značilnosti zdravila/navodilu za uporabo zdravila, ki bo radioaktivno označevano.
Effects on ability to drive and use machine s
Vpliv na sposobnost vožnje in upravljanja s stroji
Effects on ability to drive and use machines
4.7. Vpliv na sposobnost vožnje in upravljanja s stroji
Effects on ability to drive and use machines
Vpliv na sposobnost voţnje in upravljanja s stroji
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja s stroj
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja s strojev
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja s strojevi
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja s troji
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja strojev
Effects on ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanje s stroji
Effects on ability to drive and use machines
Vpliv na sposobnost za vožnjo in upravljanja s stroji
Effects on ability to drive and use machines
Vplivi na sposobnost vožnje in upravljanja s stroji
Effects on ability to drive or use machines
Vpliv na sposobnost vožnje in upravljanja s stroji
Effects on ability to drive or use machines
Vpliv na sposobnost vožnje in upravljanja strojev
Effects on ability to drive or use machines following treatment by Yttrium (90Y)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Za informacije o kontraindikacijah za določena z itrijem (90Y) označena zdravila, ki so pripravljena z uporabo YTRACISa, upoštevajte Povzetek glavnih značilnosti zdravila/navodilo za uporabo zdravila, ki naj bi ga označili z radioaktivnim izotopom.
Effects on ACR and PASI in IMPACT and IMPACT 2
Učinki na ACR in PASI v študijah IMPACT in IMPACT 2
Effects on ACR20, Structural Joint Damage and Physical Function at week 54, ATTRACT
Učinki na ACR 20, strukturno okvaro sklepov in funkcijo sklepov v 54. tednu, študija ATTRACT
Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE
Učinki na ACRn, strukturno poškodbo sklepov in funkcijo sklepov v 54. tednu, ASPIRE
Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE
Učinki na ACRn, strukturno poškodbo sklepov in funkcijo sklepov v 54. tednu, ASPIRE placebo
Effects on breast tissue
Vplivi na tkivo dojk
Effects on cognitive function
Vplivi na kognitivno funkcijo
Effects on drug levels
(indukcija CYP3A4)
Effects on drug levels
aluminijev hidroksidni-magnezijev
Effects on drug levels
boceprevir/efavirenz
Effects on drug levels
emtricitabinom,
Effects on drug levels
Interakcij z efavirenzom,
Effects on drug levels
karbamazepin/dizoproksiltenofovirije v fumarat
Effects on drug levels
ledipasvir/sofosbuvir
Effects on drug levels
neokužene prostovoljce.
Effects on drug levels
reduktaze:
Effects on drug levels
simeprevir:
Effects on drug levels
uporabe z zdravilom
Effects on drug levels
Učinek na koncentracijo
Effects on drug levels
Vplivi na koncentracije zdravil
Effects on drug levels
vrednosti progesterona ostale
Effects on drug levels
Študije medsebojnega delovanja
Effects on drug levels Least Squares
Učinek na koncentracije zdravil Srednji količnik po metodi najmanjših kvadratov
Effects on drug levels Mean percent change in AUC,
o pri osebah, ki so prejemale
Effects on drug levels Mean percent change in AUC,
odstotka za ≤ 20 % ali zvečanju
Effects on drug levels Mean percent change in AUC,
stabilne koncentracije).
Effects on drug levels Mean percent change in AUC,
Učinki na koncentracije učinkovin
Effects on endocrine active and reproductive system organs were not observed in a chronic cynomolgus monkey toxicity study and reproductive performance was not affected in IL-6 deficient mice.
V študiji kroničnih toksičnih učinkov pri opicah cynomolgus niso opazili učinkov na endokrino aktivnih in reproduktivnih organih in reproduktivna sposobnost miši s pomanjkanjem IL-6 ni bila prizadeta.
Effects on fertility are unknown (see section 5.3 for preclinical information)
Učinki na plodnost niso znani (glejte poglavje 5.3 za predklinične podatke).
Effects on fertility are unknown (see section 5.3 for preclinical information).
Učinki na plodnost niso znani (glejte poglavje 5.3 za predklinične informacije)
Effects on fertility are unknown (see section 5.3 for preclinical information).
Učinki na plodnost niso znani (glejte poglavje 5.3 za predklinične informacije).
Effects on fertility cannot be excluded.
Možni učinki na plodnost pa se ne dajo izključiti.
Effects on glycaemic control in obese subjects with type 2 diabetes
Učinki na glikemični nadzor pri debelih preiskovancih s sladkorno boleznijo tipa 2
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
Pri vsaki vrsti so odkrili učinke na hematološke parametre, vključno zodmerkom povezanimi znižanji koncentracij levkocitov v obtoku pri miših in nespecifičnim znižanjem koncentracije levkocitov v obtoku pri podganah; vendar pa niso našli dokazov citotoksičnosti za kostni mozeg.
Effects on height, weight and Body Mass index (BMI)
Učinki na telesno višino, telesno maso in indeks telesne mase (ITM)
Effects on height, weight and body Mass index (BMI)
Vpliv na telesno višino, telesno maso in indeks telesne mase (ITM)
Effects on hepatic or renal function were minimal or nonexistent.
Učinki na delovanje jeter in ledvic so bili majhni ali jih ni bilo.
Effects on iron homeostasis
Učinki na homeostazo železa
Effects on lipid metabolism and cardiovascular risk
Vplivi na presnovo lipidov in srčnožilno tveganje
Effects on lipid metabolism and cardiovascular system
Učinki na presnovo lipidov in na srčnožilni sistem
Effects on male fertility in rat were observed in the form of tubular atrophy in the testes, reduction of spermatozoa in epididymides and colloid depletion in prostate and seminal vesicles at plasma exposure levels 25 times the systemic exposure in humans.
Pri plazemski izpostavljenosti, ki je bila 25-krat večja od sistemske izpostavljenosti pri ljudeh, so ugotovili učinke na plodnost podganjih samcev, ki so se kazali kot atrofija tubulov v modih, manjše število semenčic v obmodkih ter koloidno izčrpanje prostate in seminalnih vezikul.
Effects on medicinal product levels.
NARKOTIČNI ANALGETIKI
Effects on medicinal product levels.
Učinki na koncentracije učinkovin.
Effects on nervous system: dizziness (sensation of unsteadiness), headache, sleep disturbances (including difficulty sleeping and nightmares), pins and needles sensation (paresthesia).
učinki na živčevje: omotica (občutek nestabilnosti), glavobol, motnje spanja (vključno s težavami pri spanju in nočnimi morami), občutek zbadanja (parestezija),
Effects on other AEDs
Učinki na druga zdravila proti epilepsiji
Effects on renal function
Učinki na ledvično funkcijo
Effects on response and remission rate, data from ACCENT I (Week-2 responders)
Učinki na stopnjo odziva in ponovitev bolezni pri bolnikih; podatki iz študije ACCENT I (bolniki z odzivom v 2. tednu)
Effects on response rate, data from ACCENT II (week-14 responders)
Učinki na stopnjo odziva; podatki iz študije ACCENT II (bolniki z odzivom v 14. tednu)
Effects on serum uric acid and urinary excretion of uric acid
Vpliv na sečno kislino v serumu in izločanje sečne kisline v urinu
Effects on Sweat Chloride:
Učinki na kloride v znoju:
Effects on the ability to drive and use machines
Vpliv na sposobnost vožnje in upravljanja s stroji
Effects on the ability to drive and use machines are not known.
Vpliv na sposobnost vožnje in upravljanja s stroji ni znan.
Effects on the breast
Učinki na dojke
Effects on the endometrium and on the pelvic floor
Vplivi na endometrij in medenično dno
Effects on the external genitalia were observed though abiraterone acetate was not teratogenic.
Opazili so učinke na zunanja spolovila, vendar abirateronacetat ni bil tetatogen.
Effects on the heart (such as heart attack, altered heart beat or angina)
vpliv na srce (srčni infarkt, spremenjen srčni ritem ali angina pektoris)
Effects on the immune system
Vplivi na imunski sistem
Effects on the nerves controlling your muscles resulting in weakness in the arms and legs
učinek na živce, ki nadzirajo mišice, kar povzroči oslabelost rok in nog
Effects on the pharmacokinetics of other medicinal products
Učinki na farmakokinetiko drugih zdravil
Effects on the QT interval
Učinki na interval QT
Effects on the thyroid were observed in both rat (mild increases in thyroid stimulating hormone and triiodothyronine / thyroxine T3/T4 concentrations with no microscopic correlate) and monkey (depletion of colloid in males in 4-week study, and one monkey at high dose with diffuse follicular cell hyperplasia and increased thyroid stimulating hormone in 13-week study).
Vpliv na ščitnico so opažali tako pri podganah (blago zvišanje koncentracij tirotropina (TSH) in trijodtironina/tiroksina (T3/T4) brez ustreznih mikroskopskih sprememb) kot pri opicah (zmanjšanje količine koloida v ščitnici pri samcih v 4-tedenski študiji in en primer opice, pri kateri je po dajanju visokih odmerkov prišlo do difuzne hiperplazije folikularnih celic in zvišanja koncentracije tirotropina v 13-tedenski študiji).
Effects on the uterus
Učinki na maternico
Effects on unbound exposure could be expected (has not been studied) and therefore caution is advised in patients with moderate hepatic impairment.
Pri jetrni okvari lahko pričakujemo učinke zaradi izpostavljenosti nevezanemu zdravilu (ki pa še niso proučeni) in zato svetujemo previdnost pri bolnikih z zmerno jetrno okvaro.
Effects on vaccines: Flebogamma DIF may reduce the effectiveness of certain types of vaccines (live attenuated virus vaccines).
Učinki na cepiva: zdravilo Flebogamma DIF lahko zmanjša učinkovitost določenih vrst cepiv (živih oslabljenih virusnih cepiv).
Effects on vision; redness of the eye, effects on colour vision, eye pain and discomfort, light sensitivity
vpliv na vid: pordelost očesa, vpliv na zaznavanje barv, bolečina in neprijeten občutek v očesu, občutljivost za svetlobo
Effects seen in blood tests
Učinki, opaženi pri krvnih preiskavah
Effects suspected to be due to overdose have not been reported.
O učinkih, za katere bi sumili, da so posledica prevelikega odmerjanja, niso poročali.
Effects unknown
Učinki niso znani.
effects.
neželene učinke.
effects.
neželenih učinkov.
effects; a decrease in furosemide dose of up to 50% may be required.
kliničnih učinkov; potrebno je lahko do
Effentora 100 micrograms buccal tablets
Effentora 100 mikrogramov bukalne tablete
Effentora 200 micrograms buccal tablets
Effentora 200 mikrogramov bukalne tablete
Effentora 400 micrograms buccal tablets
Effentora 400 mikrogramov bukalne tablete
Effentora 400 micrograms buccal tablets Fentanyl
Effentora 400 mikrogramov bukalne tablete fentanil
Effentora 600 micrograms buccal tablets
Effentora 600 mikrogramov bukalne tablete
Effentora 600 micrograms buccal tablets Fentanyl
Effentora 600 mikrogramov bukalne tablete fentanil
Effentora 800 micrograms buccal tablets
Effentora 800 mikrogramov bukalne tablete
Effentora 800 micrograms buccal tablets Fentanyl
Effentora 800 mikrogramov bukalne tablete fentanil
Effentora employs a delivery technology which utilises an effervescent reaction which enhances the rate and extent of fentanyl absorbed through the buccal mucosa.
Dostava zdravila Effentora poteka na osnovi efervescentne reakcije, ki izboljša stopnjo in količino fentanila, absorbiranega skozi lično sluznico.
Effentora is a pain-relieving medicine known as an opioid, which is used to treat breakthrough pain in adult patients with cancer who are already taking other opioid pain medicines for their persistent (around-the-clock) cancer pain.
Effentora je zdravilo za lajšanje bolečine, znano kot opioid, ki se uporablja za zdravljenje prebijajoče bolečine pri odraslih bolnikih s karcinomom, ki že jemljejo druga opioidna zdravila za lajšanje trdovratne (24-urne) bolečine zaradi karcinoma.
Effentora is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
Zdravilo Effentora se ne priporoča pri bolnikih, ki so v zadnjih 14 dneh dobili zaviralce monoamin- oksidaze (MAO), saj poročajo o resnih in nepredvidljivih povečanjih učinkov zaviralcev MAO z opioidnimi analgetiki.
Effentora is used to treat ‘breakthrough’ pain in adults with cancer who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Zdravilo Effentora se uporablja za zdravljenje „prebijajoče“ bolečine pri odraslih ljudeh z rakom, ki že jemljejo opioide (zdravila iz skupine protibolečinskih zdravil, kamor spadata morfin in fentanil) za nadzor dolgotrajne bolečine pri raku.
Effentora may be used before or after, but not during, meals.
Zdravilo Effentora lahko uporabite pred obroki ali po njih, vendar ne med njimi.
Effentora must not be prescribed in pain other than breakthrough cancer pain
Zdravila Effentora ni dovoljeno predpisati za drugo bolečino, kot za prebijajočo bolečino zaradi raka
Effentora must not be prescribed in patients below 18 years of age The educational material for patients shall consist of the following three items:
Zdravila Effentora ni dovoljeno predpisati bolnikom, mlajšim od 18 let Izobraževalno gradivo za bolnike mora vsebovati naslednje tri postavke:
Effentora must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression, or who have severe obstructive lung conditions (diseases that severely impede breathing).
Zdravila Effentora ne smejo uporabljati bolniki, ki še ne jemljejo opioidov za vzdrževanje nadzora nad bolečino, kakor tudi ne tisti, ki imajo resno respiratorno depresijo ali obolenje s hudo obstrukcijo pljuč (bolezen, pri kateri je dihanje močno ovirano).
EFFENTORA prescribing guide
Vodnika za predpisovanje zdravila EFFENTORA
Effentora should be administered with caution to patients with moderate or severe hepatic or renal impairment (see section 4.4).
Zdravilo Effentora je treba pri bolnikih z zmerno ali hudo okvaro jeter ali ledvic uporabljati previdno (glejte poglavje 4.4).
Effentora should be individually titrated to an “effective” dose that provides adequate analgesia and minimises adverse reactions.
Zdravilo Effentora je treba titrirati individualno do ‘učinkovitega’ odmerka, ki daje ustrezne analgetične rezultate in zmanjšuje neželene reakcije na najmanjšo možno mero.
Effentora should not be used during pregnancy unless you have discussed this with your doctor.
Zdravila Effentora ne smete uporabljati med nosečnostjo, razen če ste se tako dogovorili s svojim zdravnikom.
Effentora should only be administered with extreme caution in patients who may be particularly susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure or impaired consciousness.
Zdravilo Effentora je treba bolnikom, ki so posebno občutljivi na intrakranialne učinke zadrževanja CO2, na primer take, pri katerih je dokazan povečan intrakranialni tlak ali zmanjšana zavest, dajati izjemno previdno.
Effentora tablet once exposed to moisture utilises an effervescent reaction to deliver the active substance.
Ko so tablete Effentora izpostavljene vlagi, se razkrojijo in sprostijo zdravilno učinkovino.
Effentora with food and drink and alcohol
Zdravilo Effentora skupaj s hrano, pijačo in alkoholom
Efficacy (%)
Učinkovitost (%)
Efficacy (95% CI)b
Učinkovitost (95-% IZ)b
Efficacy (95% CI)c
Učinkovitost (95-% IZ)c
Efficacy (95% CI)c all strains regardless of match
Učinkovitost (95 % IZ)c vsi sevi, ne glede na ujemanje
Efficacy (95% CI)c matched strains
Učinkovitost (95 % IZ)c ujemajoči se sevi
Efficacy against any severity by rotavirus genotype
Učinkovitost proti bolezni katere koli intenzitete glede na genotip rotavirusa
Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3% (95% CI: 40.3, 89.4), against
V kombinaciji protokolov je bila na koncu študije učinkovitost proti s HPV 6, HPV 11, HPV 16 ali HPV 18 povezanim VIN 2/3 73,3 % (95-odstotni IZ: 40,3; 89,4), proti s HPV 6, HPV 11, HPV 16 ali
Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3% (95% CI: 40.3, 89.4), against HPV
V kombinaciji protokolov je bila na koncu študije učinkovitost proti s HPV 6, HPV 11, HPV 16 ali HPV 18 povezanim VIN 2/3 73,3 % (95-odstotni IZ: 40,3; 89,4), proti s HPV 6, HPV 11, HPV 16 ali
Efficacy against invasive disease
Učinkovitost proti invazivnim okužbam
Efficacy against otitis media
Učinkovitost proti vnetju srednjega ušesa
Efficacy against vaccine-type (VT) pneumococcal CAP and IPD was assessed in a large-scale randomised double-blind, placebo-controlled study (Community-Acquired Pneumonia Immunization Trial in Adults–CAPiTA) in the Netherlands.
Učinkovitost proti CAP in IPD, povzročenima z vrsto, prisotno v cepivu (VT – vaccine-type), so ocenili v obsežni, randomizirani, dvojno slepi s placebom nadzorovani študiji (CAPiTA - Community- Acquired Pneumonia Immunization Trial in Adults) na Nizozemskem.
Efficacy analyses from ET743-OVA-301
Analize učinkovitosti za ET743-OVA-301
efficacy and loss of HIV
učinkovitostjo in izgubo
Efficacy and safety data in patients with hypophosphatasia >18 years old are limited.
Podatki o učinkovitosti in varnosti zdravila pri bolnikih s hipofosfatazijo, starih > 18 let, so omejeni.
Efficacy and safety evaluation for adolescent patients with type 2 diabetes mellitus has been made using data from adolescent and adult patients with type 1 diabetes mellitus and adult patients with type 2 diabetes mellitus.
Korist in varnost zdravila pri mladostnikih s sladkorno boleznijo tipa 2 so ocenili s pomočjo podatkov, pridobljenih pri mladostnikih in odraslih s sladkorno boleznijo tipa 1 ter odraslih bolnikih s sladkorno boleznijo tipa 2.